|
C5ORF41 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.04489808103881E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.86370038793393E-10 |
| Normal-vs-Stage2 |
1.97409999458387E-08 |
| Normal-vs-Stage3 |
4.56720217201223E-11 |
| Normal-vs-Stage4 |
1.82870385501133E-11 |
| Stage1-vs-Stage2 |
9.565200E-01 |
| Stage1-vs-Stage3 |
2.712200E-01 |
| Stage1-vs-Stage4 |
8.760200E-02 |
| Stage2-vs-Stage3 |
4.198400E-01 |
| Stage2-vs-Stage4 |
2.071400E-01 |
| Stage3-vs-Stage4 |
5.603200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.53279652595984E-11 |
| Normal-vs-AfricanAmerican |
9.93929999999477E-05 |
| Normal-vs-Asian |
1.76430003939743E-09 |
| Caucasian-vs-AfricanAmerican |
2.620800E-01 |
| Caucasian-vs-Asian |
9.005600E-01 |
| AfricanAmerican-vs-Asian |
2.795000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.48709941530478E-11 |
| Normal-vs-Female |
1.87829973796738E-10 |
| Male-vs-Female |
2.332600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.03589972342422E-10 |
| Normal-vs-Age(41-60Yrs) |
1.08450026736762E-10 |
| Normal-vs-Age(61-80Yrs) |
4.43259873250668E-11 |
| Normal-vs-Age(81-100Yrs) |
2.336600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.505000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.431200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.312200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.988600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.133600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.310800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.493930E-02 |
| Classical-VS-Follicular |
5.154400E-01 |
| Classical-VS-Other |
1.854630E-01 |
| Classical-VS-Normal |
1.23790000472468E-09 |
| Tall-VS-Follicular |
1.288650E-01 |
| Tall-VS-Other |
6.177400E-01 |
| Tall-VS-Normal |
2.0792034760575E-11 |
| Follicular-VS-Other |
3.241000E-01 |
| Follicular-VS-Normal |
1.71030001272499E-09 |
| Other-VS-Normal |
5.190400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.3933969229879E-11 |
| Normal-vs-N1 |
3.10160008787363E-10 |
| N0-vs-N1 |
4.868800E-01 |
|
|
